Overview
Spire Healthcare Group plc is a prominent private healthcare provider based in the United Kingdom. Specializing in diagnostics, surgery, and various patient treatments, the company operates a network of hospitals and clinics across the country. Since its establishment, Spire has focused on delivering high-quality care through significant investments in medical technology and facilities. Key projects include the expansion of its oncology services and the incorporation of advanced technologies like robotic surgery systems, enhancing both the precision and efficiency of procedures offered. Financially, the company targets sustainable growth by capitalizing on the increasing demand for private healthcare, emphasizing patient satisfaction and operational excellence as core drivers of its business strategy.
Basic Stats
The share price of Spire Healthcare Group plc as of 5 September 2025 is 212.00 GBX / share. This is a decrease of -2.30% from the prior week. The market cap (or net worth) of Spire Healthcare Group plc as of 5 September 2025 is 857.26 GBX MM.
The Factor Analysis chart (below right) shows a view of Spire Healthcare Group plc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 857.26 MM |
| EV | 1,215.06 MM |
| Shares Out. | 400.59 MM |
| Earnings Date | |
| EPS (TTM) | 0.05 |
| Dividend Yield | 1.07 % |
| Ex-Dividend Date | 2025-05-22 |
| Borrow Rate | 0.73 |
| Short Shares Avail. | 2.30 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -15.75 % |
| Volatility (1 yr) | 0.29 |
| Beta | 0.69 |
| Sharpe Ratio (1 yr) | -0.68 |
| Sortino Ratio (1 yr) | -0.95 |
| PE Ratio | 46.34 |
| Price/Book | 1.17 |
| Price/TBV | 2.92 |
| Book/Market | 0.86 |
| EBIT/EV | 0.02 |
| EBIT(3yr avg)/EV | 0.02 |
| ROA | |
| ROE | |
| ROIC | 0.01 |
| CROIC | -0.01 |
| OCROIC | 0.12 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 38.54 /100 |
| Profitability | 46.30 /100 |
| Quality Score | |
| Value Score | 49.00 /100 |
| Momentum Score | 51.06 /100 |
| Stability (Low Vol) Score | 73.77 /100 |
| Analyst Sentiment | 84.12 /100 |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 5.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Spire Healthcare Group plc is 295.07 GBX. The forecasts range from a low of 271.69 GBX to a high of 315.00 GBX. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Spire Healthcare Group plc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-09-09 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-09-08 | Berenberg Bank | Buy | Reiterate | |
| 2022-08-17 | Barclays | Overweight | Reiterate | |
| 2022-07-19 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2022-07-12 | Berenberg Bank | Buy | Reiterate | |
| 2022-06-30 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-06-30 | Berenberg Bank | Buy | Reiterate | |
| 2022-06-21 | Berenberg Bank | Buy | Initiate | |
| 2022-05-31 | Barclays | Overweight | Reiterate | |
| 2022-04-05 | Barclays | Overweight | Reiterate | |
| 2022-03-24 | RBC Capital Markets | Sector Perform | Reiterate | |
| 2022-03-10 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2022-02-04 | RBC Capital Markets | Reiteration | Reiterate | |
| 2022-01-04 | JP Morgan Cazenove | Reiteration | Reiterate | |
| 2021-12-14 | Barclays | Reiteration | Reiterate | |
| 2021-12-03 | Barclays | Reiteration | Reiterate | |
| 2021-10-21 | Barclays | Overweight | Reiterate | |
| 2021-09-10 | Barclays | Overweight | Upgrade | |
| 2021-05-27 | Liberum Capital | Hold | Reiterate | |
| 2021-05-26 | Peel Hunt LLP | Buy | Reiterate | |
| 2021-05-13 | Numis | Add | Reiterate | |
| 2021-02-09 | Liberum Capital | Hold | Downgrade | |
| 2020-09-28 | JP Morgan Cazenove | Overweight | Upgrade | |
| 2020-05-11 | RBC Capital Markets | Sector Perform | Downgrade | |
| 2020-01-08 | Peel Hunt LLP | Add | Reiterate | |
| 2019-11-12 | Liberum Capital | Hold | Reiterate | |
| 2019-09-16 | UBS | Neutral | Reiterate | |
| 2019-09-16 | Peel Hunt LLP | Add | Reiterate | |
| 2019-09-09 | RBC Capital Markets | Outperform | Reiterate | |
| 2019-08-09 | Barclays | Underweight | Reiterate | |
| 2019-05-16 | Numis | Buy | Reiterate | |
| 2019-05-10 | Barclays | Underweight | Reiterate | |
| 2019-02-28 | Numis | Buy | Reiterate | |
| 2019-02-12 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2018-09-18 | Berenberg Bank | Sell | Reiterate | |
| 2018-07-08 | Berenberg Bank | Sell | Downgrade | |
| 2018-03-12 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2018-03-01 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2017-11-28 | Berenberg Bank | Buy | Reiterate | |
| 2017-09-21 | Berenberg Bank | Hold | Reiterate | |
| 2017-09-15 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2017-06-21 | Berenberg Bank | Buy | Reiterate | |
| 2017-06-01 | Jefferies | Hold | Reiterate | |
| 2017-03-14 | Berenberg Bank | Buy | Reiterate | |
| 2017-01-18 | Berenberg Bank | Buy | Reiterate | |
| 2017-01-16 | Credit Suisse | Underperform | Reiterate | |
| 2017-01-12 | Numis | Add | Reiterate | |
| 2016-09-09 | Berenberg Bank | Buy | Reiterate | |
| 2016-08-10 | Berenberg Bank | Buy | Reiterate | |
| 2016-07-26 | Jefferies | Hold | Reiterate | |
| 2016-06-08 | Berenberg Bank | Buy | Reiterate | |
| 2016-04-01 | Berenberg Bank | Buy | Reiterate | |
| 2016-03-31 | Jefferies | Hold | Reiterate | |
| 2016-03-30 | Nomura | Buy | Initiate | |
| 2016-03-23 | Berenberg Bank | Buy | Reiterate | |
| 2016-03-18 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2016-02-12 | Berenberg Bank | Buy | Reiterate | |
| 2016-01-11 | Barclays | Overweight | Reiterate | |
| 2016-01-11 | Berenberg Bank | Buy | Reiterate | |
| 2015-11-26 | Berenberg Bank | Buy | Reiterate | |
| 2015-11-24 | JP Morgan Cazenove | Neutral | Reiterate | |
| 2015-11-16 | Jefferies | Hold | Downgrade | |
| 2015-11-13 | JP Morgan Cazenove | Neutral | Downgrade | |
| 2015-11-12 | Berenberg Bank | Buy | Reiterate | |
| 2015-08-21 | Numis | Add | Reiterate | |
| 2015-06-22 | Numis Securities | Add | Reiterate | |
| 2015-05-12 | Numis Securities | Add | Reiterate | |
| 2015-04-15 | Numis Securities | Add | Upgrade | |
| 2015-03-24 | Numis Securities | Hold | Downgrade | |
| 2015-03-18 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2015-01-26 | Investec | Hold | Downgrade | |
| 2015-01-13 | Numis Securities | Buy | Reiterate | |
| 2015-01-13 | Morgan Stanley | Equal-weight | Reiterate | |
| 2015-01-13 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-11-28 | Morgan Stanley | Equal-weight | Downgrade | |
| 2014-11-20 | Investec | Buy | Reiterate | |
| 2014-11-19 | Numis Securities | Buy | Reiterate | |
| 2014-11-06 | Morgan Stanley | Overweight | Reiterate | |
| 2014-11-06 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-11-06 | Investec | Buy | Reiterate | |
| 2014-11-06 | Numis Securities | Buy | Reiterate | |
| 2014-10-28 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2014-08-28 | Numis Securities | Buy | Reiterate | |
| 2014-08-28 | Investec | Buy | Initiate | |
| 2023-09-15 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2023-09-15 | Barclays | Overweight | Reiterate | |
| 2023-09-18 | Berenberg Bank | Buy | Reiterate | |
| 2024-04-18 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2024-04-17 | Berenberg Bank | Buy | Reiterate | |
| 2024-02-26 | JP Morgan Cazenove | Overweight | Reiterate | |
| 2023-11-13 | RBC Capital Markets | Outperform | Reiterate | |
| 2024-02-29 | Berenberg Bank | Buy | Reiterate | |
| 2024-09-17 | Berenberg Bank | Buy | Reiterate | |
| 2025-03-06 | Deutsche | Buy | Reiterate | |
| 2025-07-31 | Berenberg Bank | Buy | Reiterate | |
| 2025-08-05 | JP Morgan Cazenove | Overweight | Reiterate |
